Form 4: Alnylam Director Exercises, Sells Shares

Alnylam Pharmaceuticals Director Dennis A. Ausiello exercised stock options and sold an equivalent number of shares on August 14, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Director Dennis A. Ausiello of Alnylam Pharmaceuticals, Inc. (ALNY) executed a series of transactions on August 14, 2025.
• These transactions were conducted pursuant to a Rule 10b5-1(c) trading plan adopted on May 15, 2025.
• Ausiello exercised stock options to acquire a total of 31,448 shares of common stock at various strike prices ranging from $72.01 to $189.87.
• Simultaneously, Ausiello sold 31,448 shares of common stock at weighted average sales prices ranging from $430.81 to $442.66.
• Following these transactions, Ausiello directly holds 911 shares of common stock.
• Additionally, 3,500 shares of ALNY common stock are held indirectly in a trust where Ausiello's spouse is the trustee, bringing the total beneficial ownership to 4,411 shares.

Sentiment

Score: 6

Explanation: The filing details routine insider transactions (exercise of vested options and subsequent sale of shares) conducted under a pre-arranged 10b5-1 plan. This is a common compensation and liquidity event for executives and directors and does not typically indicate a change in company fundamentals or outlook.

Positives

• The exercise of stock options indicates that the shares were significantly 'in the money', reflecting a substantial gain from the original grant prices.
• The transactions were executed under a Rule 10b5-1 trading plan, which suggests a pre-scheduled, non-discretionary sale, often mitigating negative market interpretations of insider selling.

Negatives

• The sale of a significant number of shares by a director reduces their direct ownership stake in the company.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• 3,500 shares of ALNY common stock are held in a trust, of which the reporting person's spouse is the trustee, representing indirect beneficial ownership.

Stakeholder Impact

• Minimal direct impact on shareholders as these are routine insider transactions under a pre-arranged plan.
• The transactions reflect a director monetizing vested equity compensation, which is a standard practice.

Key Dates

Recommendation

The filing is a routine Form 4 detailing the exercise of vested stock options and the subsequent sale of shares by a director under a pre-arranged Rule 10b5-1 trading plan. Such transactions are typically part of an executive's long-term compensation and liquidity strategy and do not inherently signal a change in the company's fundamental outlook or warrant a change in investment thesis based solely on this filing.

Keywords

Alnylam Pharmaceuticals, ALNY, SEC Form 4, Insider Trading, Stock Options, Rule 10b5-1, Biotechnology, Pharmaceuticals, Director Transactions